Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pindolol
Drug ID BADD_D01776
Description Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Indications and Usage Pindolol is indicated in the management of hypertension.[L32353] In Canada, it is also indicated in the prophylaxis of angina.[L32388]
Marketing Status approved; investigational
ATC Code C07AA03
DrugBank ID DB00960
KEGG ID D00513
MeSH ID D010869
PubChem ID 4828
TTD Drug ID D0F2PO
NDC Product Code 72789-099; 72789-294; 49169-0006; 29033-028; 57664-655; 72789-293; 0378-0127; 76385-132; 62559-560; 70710-1063; 64330-109; 70771-1134; 70771-1135; 76385-131; 57664-656; 62559-561; 0378-0052; 72789-100; 29033-029; 70710-1064; 10135-743; 10135-744
UNII BJ4HF6IU1D
Synonyms Pindolol | Prindolol | Visken | LB-46 | LB 46 | LB46
Chemical Information
Molecular Formula C14H20N2O2
CAS Registry Number 13523-86-9
SMILES CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Musculoskeletal disorder15.03.05.025--Not Available
Ocular discomfort06.08.03.008--Not Available
Coronary artery insufficiency24.04.04.016; 02.02.01.008--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.11.01.003--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 3th Page    First    Pre   3    Total 3 Pages